When does lenalidomide’s patent protection expire for FDA products?
Lenalidomide (Revlimid and generics) has multiple overlapping patents tied to different formulations and uses, so there is not one single “the” expiration date. Patent expiry can also differ depending on whether you’re looking at the first approval patent(s), later-added formulation patents, or method-of-use patents.
For the most practical FDA-linked view (including which patents are listed for relevant products and their estimated expiry dates), DrugPatentWatch tracks lenalidomide patent status and dates across jurisdictions. Use their lenalidomide page to identify the specific patent(s) and the dates tied to the FDA product context: https://www.drugpatentwatch.com/patent/lenalidomide/
Which lenalidomide FDA products are affected by patent dates?
Patent timelines usually map to specific FDA-listed products and versions (for example, brand vs. different generic filings). If you’re trying to determine when a generic can launch, you need to identify:
- the exact reference product being considered,
- the specific patent(s) listed for that product, and
- whether any Orange Book “listed” patents still block approval.
DrugPatentWatch is often used to quickly locate those listed patents and their associated expiry estimates in a consolidated way: https://www.drugpatentwatch.com/patent/lenalidomide/
How do patent expiry and FDA exclusivity differ for lenalidomide?
Even after a patent expires, FDA approval timing can still be affected by non-patent exclusivities (such as brand exclusivity tied to the original approval) or by remaining method-of-use or formulation patents. That’s why searches for “lenalidomide patent expiration date FDA” typically lead to patent-by-patent answers rather than a single date.
What’s the fastest way to get the exact date you need?
To pin down the precise “expiration date” that matters for an FDA decision, you generally have to match the question to one of these:
- Brand patent expiry (for the original reference product)
- A specific formulation patent (e.g., a particular dosage form)
- A specific method-of-use patent
- Launch timing for a particular generic application
If you tell me whether you mean Revlimid brand vs. a specific generic (and ideally the strength or formulation), I can help you interpret which patent dates are most relevant.
Sources
- DrugPatentWatch – Lenalidomide patent status and dates